Page last updated: 2024-11-05

uridine diphosphate n-acetylglucosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

UDP-GlcNAc is a key sugar nucleotide involved in the biosynthesis of numerous essential biomolecules, including glycosaminoglycans, glycoproteins, and N-linked glycans. It serves as a donor of N-acetylglucosamine in various metabolic pathways, playing a crucial role in cell signaling, protein trafficking, and immune responses. UDP-GlcNAc is synthesized from glucose-6-phosphate through a series of enzymatic reactions involving UDP-glucose and glucosamine-6-phosphate. Its synthesis and utilization are tightly regulated, ensuring proper cellular function and maintaining homeostasis. Research on UDP-GlcNAc focuses on understanding its role in various biological processes, including its involvement in disease development, such as cancer and inflammatory disorders. Studying UDP-GlcNAc provides insights into potential therapeutic targets and drug development strategies for treating these conditions.'

Uridine Diphosphate N-Acetylglucosamine: Serves as the biological precursor of insect chitin, of muramic acid in bacterial cell walls, and of sialic acids in mammalian glycoproteins. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10705
MeSH IDM0022352

Synonyms (12)

Synonym
uridine pyrophosphoacetylglucosamine
uridine diphospho-n-acetylglucosamine
uridine diphosphate n-acetylglucosamine
528-04-1
[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
BMSE000188
uridine 5'-(trihydrogen diphosphate), p'-(2-(acetylamino)-2-deoxy-alpha-d-glucopyranosyl) ester
udpgnac
uridine diphosphate-n-acetylglucosamine
udp acetylglucosamine
[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl] [[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] hydrogen phosphate
DTXSID10912327

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This study demonstrates that after the induction of diabetes there is a rapid increase in the bioavailability of substrates utilized in the synthesis of glycoproteins and glycosaminoglycans."( Effects of early diabetes on uridine diphosphosugar synthesis in the rat renal cortex.
Cortes, P; Dumler, F; Levin, NW; Sastry, KS; Verghese, CP, 1982
)
0.26

Dosage Studied

ExcerptRelevanceReference
" The sensitivity of the PAb-mAb sandwich assay, as determined by the dose-response effect for AGR-GnT-III, was 10 ng/ml."( Determination of UDP-N-acetylglucosamine: beta-D-mannoside-1,4-N-acetylglucosaminyltransferase-III in patients sera with chronic hepatitis and liver cirrhosis using a monoclonal antibody.
Byun, SM; Choe, YK; Chung, TW; Kim, CH; Kim, HJ; Kim, KA; Kim, KS; Kim, YD; Kwon, DH; Song, EY, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (680)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990283 (41.62)18.7374
1990's124 (18.24)18.2507
2000's143 (21.03)29.6817
2010's105 (15.44)24.3611
2020's25 (3.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.19 (24.57)
Research Supply Index6.55 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.14%)5.53%
Reviews23 (3.30%)6.00%
Case Studies3 (0.43%)4.05%
Observational0 (0.00%)0.25%
Other669 (96.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]